Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 29, 2024 (filed on Mar 08, 2024)Insider Name:Cundy Kenneth COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:72,613Price:--
-
Feb 29, 2024 (filed on Mar 01, 2024)Insider Name:Cundy Kenneth COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:72,613Price:--
-
Dec 18, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:300,000Price:--
-
Dec 18, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-300,000Price:--
-
Nov 13, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Oct 06, 2023 (filed on Oct 11, 2023)Insider Name:Cunningham, Richard AnthonyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:600,000Price:--
-
Oct 06, 2023 (filed on Oct 10, 2023)Insider Name:Shah Bimal R.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:26,097Price:--
Filings by filing date
-
Feb 29, 2024 (filed on Mar 08, 2024)Insider Name:Cundy Kenneth COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:72,613Price:--
-
Feb 29, 2024 (filed on Mar 01, 2024)Insider Name:Cundy Kenneth COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:72,613Price:--
-
Dec 18, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:300,000Price:--
-
Dec 18, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-300,000Price:--
-
Nov 13, 2023 (filed on Dec 20, 2023)Insider Name:English Aron R.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Oct 06, 2023 (filed on Oct 11, 2023)Insider Name:Cunningham, Richard AnthonyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:600,000Price:--
-
Oct 06, 2023 (filed on Oct 10, 2023)Insider Name:Shah Bimal R.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:26,097Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Jfl Capital Management 1017 Rr 620 S, Suite 107 LAKEWAY TX 78734 |
Tel: | N/A |
Website: | https://www.anebulo.com |
IR: | See website |
Key People | ||
N/A |
Business Overview |
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company's lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system. |
Financial Overview |
For the six months ended 31 December 2023, Anebulo Pharmaceuticals Inc revenues was not reported. Net loss decreased 19% to $5.2M. Lower net loss reflects Research and development - Balancing decrease of 23% to $2.3M (expense), General and administrative - Balancing decrease of 26% to $1.4M (expense), Compensation and related benefits decrease from $45K (expense) to $0K. |
Employees: | 2 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $71.15M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$10.66M as of Dec 31, 2023 |
Net annual income (TTM): | -$10.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$9.58M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 25,933,217 as of Feb 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |